Cardiovascular and Interventional Radiological Society of Europe

September 25-28 | ONLINE


September 25-28 | ONLINE


September 25-28 | ONLINE


September 25-28 | ONLINE

September 25-28 | ONLINE

EventsInterventional oncology

Interventional oncology

Explore the IO track at the CIRSE 2021 Summit!

Minimally invasive cancer care continues to be a rapidly developing field, and interventional oncology has become an exciting component of the CIRSE Annual Meeting. The broad range of topics covered by IO will once again be featured in this year’s programme.

Focus sessions will cover mCRC and intra-arterial treatment, renal cancer management, and how to know when we’re doing a good job in cancer care. Expert round table sessions will discuss how to treat a medium to large unresectable HCC, and immuno-oncology’s relation to interventional oncology. Additionally, a hot topic symposium will address if there’s still a place for TARE in HCC, and further case based discussions and controversy sessions will shine a spotlight on all aspects of the fourth pillar of cancer care.

TARE in HCC treatment

We sat down with Dr. Edward Kim from Mount Sinai Hospital in New York/US to discuss the current role of TARE in HCC treatment, its key advantages, the specific approaches used at his instruction as well as patient selection and its future as a first-line therapy.

The best IO training offers practitioners education on imaging and image guided therapy, but also on oncology. It should expose them to the full oncology spectrum, namely through multidisciplinary tumour boards, and to patients through pre and post treatment consultation. CIRSE has a played great role in IO training by building a dedicated congress in the form of ECIO, and by including a dedicated IO track every year at the CIRSE Annual Congress.

Don’t miss these exciting sessions!

HTS 1103 – There is still a place for TARE in HCC

Sunday, September 26, 14:30-15:30 CEST

  • Before surgical resection: the Mount Sinai approach
    E. Kim (New York/NY/USA)
  • In localised tumours: dosisphere concept
    Y. Rolland (Rennes/FR)
  • In advanced HCC: results of the clinical trials
    J. Ricke (Munich/DE)
  • Combined with immunotherapy: the future?
    B. Sangro (Pamplona/ ES)

ERT 1203 – Immuno oncology and interventional oncology

Sunday, September 26, 16:00-17:00 CEST

  • Immuno oncology with and without IO – why or why not?
    D. Arnold (Hamburg/DE)
  • IO preparing the path for immuno oncology
    D. Sze (Stanford/CA/USA)
  • Basic evidence of IO in immuno oncology
    S. Goldberg (Jerusalem/IL/USA)
  • Practical evidence of IO in immuno oncology
    L. Tselikas (Villejuif/FR)

MPI 1704 – Upcoming clinical trials in interventional oncology II: Meet the PI

Monday, September 27, 13:00-14:00 CEST

  • Phase Ib/randomized phase II study combining percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: the CHOPIN trial
    T. Tong (Leiden/NL)
  • Evaluating the effectiveness of Yttrium-90 glass microspheres in hepatocellular carcinoma, intrahepatic Cholangiocarcinoma, and metastatic colorectal cancer in current clinical practice: the PROACTIF study
    B. Guiu (Montpellier/FR)
  • Prospective multi-center study to evaluate the correlation between safety margin and local recurrence after thermal ablation using image co-registration in patients with hepatocellular carcinoma: PROMETHEUS-study
    M. C. Burgmans (Leiden/NL)
  • Adjuvant Holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial)
    P. Hendriks (Leiden/NL)

and many more!